Amicus Therapeutics FOLD
-
Amicus Therapeutics : The Good And The Bad
By Biomed Group: Amicus Therapeutics ( FOLD ) is a biopharmaceutical company ..... with lysosomal storage diseases. Amicus ' lead programs include the small ..... combination with ERT for Pompe disease. Amicus and its partner GlaxoSmithKline …
-
Amicus' CEO Discusses Q1 2013 Results - Earnings Call Transcript
Amicus Therapeutics , Inc. ( FOLD ) Q1 2013 Results Earnings Call ..... gentlemen. And welcome to the Amicus Therapeutics First Quarter 2013 Results Conference ..... seekingalpha.com/article/1422841- amicus -ceo-discusses-q1-2013 …
-
Amicus Therapeutics' CEO Discusses Q4 2012 Results - Earnings Call Transcript
Amicus Therapeutics , Inc. ( FOLD ) Q42012 Earnings Call March ..... gentlemen. And welcome to the Amicus Therapeutics full year 2012 results conference ..... com/article/1268891- amicus - therapeutics -ceo-discusses-q4-2012 …
-
Amicus Theraputics ( FOLD ): Q4 EPS of -$0.20 beats by $0.17. Shares -1.6% AH. (PR)
Amicus Theraputics ( FOLD ): Q4 EPS of -$0.20 beats by $0.17 . Shares -1.6% AH. ( PR ) Post your comment!
-
Don't Fold On Amicus Therapeutics Just Yet
… for every rule there is an exception, and I think Amicus Therapeutics ( FOLD ) may just be that rare exception. While I realize ..... to theology than biotechnology, I do believe that Amicus 's lead drug is effective and safe, and I hope …
-
Amicus : Trial Detail Fails To Halt Share Slide
… the devil is in the detail. Amicus Therapeutics ' ( FOLD ) attempts to add more detail ..... the tide of sentiment, leaving Amicus with only the hope of some improvement ..... at first you don’t succeed Amicus , however, should be admired …
-
Amicus Therapeutics' CEO Presents Lysosomal Disease Network WORLD Symposium Data Highlights Conference (Transcript)
Amicus Therapeutics , Inc. ( FOLD ) Lysosomal Disease Network ..... gentlemen and welcome to the Amicus Therapeutics Lysosomal Disease Network WORLD ..... com/article/1189151- amicus - therapeutics -ceo-presents-lysosomal …
-
Amicus Therapeutics ([[ FOLD ]] -24.7%) tanks after reporting additional Stage 1 results from the ongoing Phase 3 study of oral migalastat HCl monotherapy in patients with Fabry disease. Initial ...
Amicus Therapeutics ( FOLD -24.7% ) tanks after reporting additional Stage 1 results from the ongoing Phase 3 study of oral migalastat HCl monotherapy …
-
Orphan Drug Mania: Amicus / Migalastat HCl
… A Brief Overview Of Amicu s And Fabry Disease The last time I took a look at the orphan drug specialist Amicus Therapeutics (NASDAQ: FOLD ) , we were all waiting on the phase III results for their flagship drug Migalastat HCL (which was Complete …
-
Amicus Therapeutics : Explaining A 47% Loss And Why I'm Still Bullish
By Ed's Stock Engineering: Amicus Theraputics ( FOLD ) is a biopharmaceutical company focused ..... later. The Story Begins In July '12 Amicus popped up on my radar screen in July ..... GSK ) expanding its partnership with Amicus for drug development. GSK has a headquarters …